renaissance capital, page-42

First 42 Last

Share
Profile

Follow
SmokeyNYY

587 Posts.

28/07/15

13:52

Post #: 15707014
Share

Originally posted by LAKings2014 ↑

Write this down and we will judge French and his team based on these quoted time frames:

1. "Our lead product candidate, TT-034,.....We expect to receive efficacy data in the fourth quarter of 2015. If the results of the trial are favorable, we anticipate commencing a Phase IIb/III trial in the second quarter of 2017."

2. "We are also developing Hepbarna, which currently is in preclinical studies, for the treatment of the hepatitis B virus, or HBV. We plan to file an investigational new drug, or IND, application in the first quarter of 2017."

3. "We plan to submit IND applications for our drug-resistant NSCLC product candidate in the third quarter of 2016..."

4. "our HBV and AMD product candidates in the first and second quarters of 2017, respectively.."

5. "In addition to TT-034 for HCV and Hepbarna for HBV, we are focusing on developing product candidates to treat AMD, OPMD and drug-resistant NSCLC. For selected product candidates, at the appropriate stage, we may collaborate with large pharmaceutical companies to further develop and, if approved, commercialize them to achieve broad product distribution."

We'll be watching, or not.

Expand

Looks like 2018 should be a great year for Benitec. Many different drugs should be in clinical trials. Key word "should" though....

BLT Price at posting: 94.5¢ Sentiment: Hold Disclosure: Held
1 Upvote

0 Great analysis

Reply

Top Stories

From the Floor with Federal Opposition Leader Peter Dutton at Diggers & Dealers 2024

TKM

Trek Metals jumps 5% as gold & REE drill run kicks off at Christmas Creek in the Kimberley

Emerald & Azure score Digger & Dealer awards

Bitcoin: Current State of Play & Where to Next | Swyftx

TNC

True North increases silver metal at QLD's Vero deposit by 20%

NEU

Neuren Pharmaceuticals dips after pediatric Angelman Syndrome Phase 2 trial results fail to impress

Dale Gillham's weekly wrap: picking resilient stocks in a volatile global market

HZR

Hazer Group reports ten days of continuous operation at graphite-manufacturing test facility

Revolutionary inverter technology leads the clean energy charge

Week 32 Wrap: AI is clearly overhyped – but did we see ‘bubble’ burst already? Plus RBA decision; Japan’s wild week & Google ruling

There are more pages in this discussion • 3 more messages in this thread...

First 42 Last

Add BLT (ASX) to my watchlist

renaissance capital, page-42

Top Stories

From the Floor with Federal Opposition Leader Peter Dutton at Diggers & Dealers 2024

Trek Metals jumps 5% as gold & REE drill run kicks off at Christmas Creek in the Kimberley

Emerald & Azure score Digger & Dealer awards

Bitcoin: Current State of Play & Where to Next | Swyftx

True North increases silver metal at QLD's Vero deposit by 20%

Neuren Pharmaceuticals dips after pediatric Angelman Syndrome Phase 2 trial results fail to impress

Dale Gillham's weekly wrap: picking resilient stocks in a volatile global market

Hazer Group reports ten days of continuous operation at graphite-manufacturing test facility

Revolutionary inverter technology leads the clean energy charge

Week 32 Wrap: AI is clearly overhyped – but did we see ‘bubble’ burst already? Plus RBA decision; Japan’s wild week & Google ruling

Featured News